NewLink looks to IPO for $66M to back cancer vaccine

An Iowa-based biotech named NewLink Genetics is gambling that its late-stage therapeutic cancer vaccine can light a fire under investors as it sets out to garner up to $66 million from an IPO.

NewLink laid out plans to sell 5.5 million shares at $10 to $12 apiece, something that biotech companies have found very difficult to accomplish this year. With the market in turmoil in recent months, the market for new biotech listings, anemic at best, has become moribund.

As we recently noted in a special report on pancreatic cancer programs, the Ames, IA-based developer is recruiting 700 pancreatic cancer patients for a Phase III study. And the biotech gained fast track and orphan drug status as an adjuvant treatment of pancreatic cancer after surgeries to remove tumor tissue.

- here's the Dow Jones report

Special Report: HyperAcute Pancreas - Biotech's 5 key attacks on pancreatic cancer

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.